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Rho Inhibitor VX-210 in Acute Traumatic
Subaxial Cervical Spinal Cord Injury:
Design of the SPinal Cord Injury Rho INhibition
InvestiGation (SPRING) Clinical Trial
Michael G. Fehlings,1 Kee D. Kim,2 Bizhan Aarabi,3 Marco Rizzo,4 Lisa M. Bond,5
Lisa McKerracher,5 Alexander R. Vaccaro,6 and David O. Okonkwo7
Abstract
Traumatic spinal cord injury (SCI) is associated with a lifetime of disability stemming from loss of motor, sensory, and
autonomic functions; these losses, along with increased comorbid sequelae, negatively impact health outcomes and quality
of life. Early decompression surgery post-SCI can enhance patient outcomes, but does not directly facilitate neural repair
and regeneration. Currently, there are no U.S. Food and Drug Administration–approved pharmacological therapies to
augment motor function and functional recovery in individuals with traumatic SCI. After an SCI, the enzyme, Rho, is
activated by growth-inhibitory factors and regulates events that culminate in collapse of the neuronal growth cone, failure
of axonal regeneration, and, ultimately, failure of motor and functional recovery. Inhibition of Rho activation is a potential
treatment for injuries such as traumatic SCI. VX-210, an investigational agent, inhibits Rho. When administered extra-
durally after decompression (corpectomy or laminectomy) and stabilization surgery in a phase 1/2a study, VX-210 was
well tolerated. Here, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind,
placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with
acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and
functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be
assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by
secondary outcomes that include question-based and task-based evaluations of functional recovery.
Keywords: motor recovery; Rho inhibition; spinal cord injury; SPRING trial; VX-210
Introduction
Acute spinal cord injury
Current estimates indicate that 245,000–353,000 indi-viduals who have suffered a spinal cord injury (SCI) are living
in the United States, and approximately 40–54 new cases per year per
million individuals occur.1,2 Common causes of SCI in the United
States are motor vehicle accidents (38–42%), falls (31–33%), sports
injuries (9–16%), and violence/other (9–18%).1,3 Worldwide, the
estimated incidence of SCI ranges from 250,000–500,000 in-
dividuals per year,4 and approximately 2.5 million people live
with an SCI.3
SCIs are often attributed to spinal cord compression and con-
tusion that occur within a fraction of a second.5 Primary damage to
the spinal cord is caused by the physical trauma, and further injury
(secondary damage) is caused by downstream pathophysiological
signaling cascades.6 This secondary damage is propagated through
several mechanisms of action, including ischemia, excitotoxicity,
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cytotoxic and vasogenic edema, lipid peroxidation/radical forma-
tion, and inflammation.7 Further, axonal regeneration is impeded
by growth-inhibiting factors that activate an intracellular master
enzyme, Rho, leading to a cascade of events culminating in col-
lapse of the neuronal growth cone.8–12 Both primary damage to
neurons and axonal projections in the spinal cord and secondary
damage post-injury result in loss of motor and sensory function in
patients who experience an SCI; a severe traumatic lesion to the
spinal cord can result in permanent paralysis below the segmental
level of the injury.13
The independent daily activities of individuals who have suf-
fered an SCI are often hampered; depending on the segmental level
and injury severity, up to 24-h attendant care may be required
for individuals with cervical SCI.14,15 Individuals with SCIs may
also experience serious comorbidities that impact quality of life,
including autonomic dysreflexia, bladder dysfunction, osteopo-
rosis, heterotopic ossification, pressure sores, reduced immune
function, chronic lifelong pain, and pulmonary and cardiovas-
cular complications.16–21 Life expectancy of individuals with
SCIs may be considerably shortened compared to age-matched
controls from the general population.1 Because an SCI affects
many aspects of life, even a partial restoration of motor func-
tion may improve patient autonomy and permit a higher quality
of life.
Treatment of spinal cord injury
A recognized standard of care for traumatic SCI is immediate
immobilization, prevention of neurogenic shock, intubation, oxy-
genation, imaging evaluation, reduction, decompression, and sta-
bilization. These measures, which help relieve direct pressure on
the spinal cord and ischemic hypoxia, may reduce secondary
damage.5,22,23 Although treatment of an acute SCI with decom-
pression and stabilization surgery may provide clinical benefit to
patients, this procedure does not directly facilitate axonal regen-
eration and repair.3 The primary goal of acute therapy for SCI is
restoration of sufficient motor function to increase autonomy.
Currently, there are no approved pharmacological treatments to
augment motor function after an SCI. Therefore, SCI represents an
extreme unmet medical need.
VX-210, a Rho inhibitor
The inability of patients to recover motor function after an SCI
stems, in part, from the failure of neurons in the central nervous
system (CNS) to regrow axons post-injury. In an ideal environ-
ment, axonal regeneration and sprouting might lead to the forma-
tion of new functional connections.7 After an acute SCI, however,
axon regeneration is impeded by a number of growth-inhibitory
proteins released by myelin debris, by the glial scar, and as a result
of inflammation.8,9,24 These factors act in concert to activate the
intracellular signaling molecule, Rho, by binding to and activat-
ing specific membrane receptors.10,11 Rho overactivation leads to
a cascade of events culminating in the collapse of axonal growth
cones12 and failure of injured axons to regenerate,8,9 as well as neu-
ronal loss25 (Fig. 1). Inhibition of Rho kinase, a downstream effector
of Rho, decreased neuronal injury in in vitro rat cortical neuron
models.26 Thus, inhibition of Rho activity represents a potential
treatment for CNS injuries such as SCI.
VX-210, formerly referred to as BA-210 or Cethrin, is a cell-
permeable derivative of the bacterial enzyme, C3 transferase, that
inhibits Rho activity through covalent modification and therefore
has the potential to independently block Rho-mediated axonal
growth cone collapse and inhibit neuronal apoptosis post-SCI.25,27
VX-210 is undergoing human investigation for its potential to
augment motor function after acute cervical SCI.
VX-210 administration
VX-210 is administered topically in a fibrin sealant to the dura
mater (extradural surface) of the spinal cord (Fig. 2A).25,28 Fibrin
sealant is extensively used in spinal cord surgery for hemostasis and
dural repairs. In rat and post-mortem porcine models, the concen-
tration of VX-210 detected in spinal cord tissue after extradural
application was dose dependent.27,29 Gradient levels of VX-210
were observed extending from the location of application within
hours of extradural administration in both a rat SCI model and
post-mortem pig spinal cord (Fig. 2B).27,29
FIG. 1. SCI-mediated Rho (A) activation and (B) inhibition by
VX-210. CSPG, chondroitin sulfate proteoglycan; MAG, myelin-
associated glycoprotein; Nogo-A, neurite outgrowth inhibitory
protein A; OMgp, oligodendrocyte-myelin glycoprotein; RGM,
repulsive guidance molecule; TNF, tumor necrosis factor.
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VX-210 in pre-clinical studies
Pre-clinical studies indicate that VX-210 has neuroregenerative
and -protective effects and can promote functional recovery post-
SCI. In rodent models of neuronal injury, treatment with VX-210
reversed the activation of Rho in spinal cord lesions, decreased
secondary tissue damage and glial scarring at the injury site, and
stimulated axon regeneration and plasticity in primary cortical
neurons.10,27,30–32 In a mouse model of acute SCI, VX-210 ad-
ministered onto the dura mater in fibrin sealant significantly im-
proved Basso, Beattie, and Bresnahan open field locomotor rating
scale scores compared to the control group (fibrin sealant alone) at
16 days post-injury when administered at the time of injury or 24 h
post-injury.27
VX-210 in early clinical evaluations: Phase 1/2a trial
The safety and tolerability of VX-210 were assessed in a multicenter,
open-label, phase 1/2a dose-ranging trial (NCT00500812).28,33,34
In this trial, 48 patients with acute traumatic cervical (n = 16) and
thoracic (n = 32) SCIs were enrolled at nine U.S. and Canadian
sites. Patients were 16–70 years of age, with an American Spinal
Injury Association Impairment Scale (AIS) grade A. Patients re-
ceived a single dose of VX-210 (range, 0.3–9.0 mg) applied to the
dura mater of the spinal cord during decompression surgery oc-
curring £7 days post-injury and were followed and assessed for
1 year after treatment.28
The most frequent treatment-emergent adverse events (AEs; by
organ system) were gastrointestinal disorders (nausea, constipa-
tion, and vomiting), general disorders (pyrexia, pain, and peripheral
edema), infections, and psychiatric disorders (insomnia, anxiety,
depression, and altered mood). Incidence of AEs was consistent
across VX-210 dose levels, and no serious AEs (SAEs) were con-
sidered by investigators to be related to treatment. The results
suggested improvement in motor strength in patients with cervical
SCI compared to patients in natural history studies.28 In patients
with thoracic SCI, the average recovery trajectory overlapped with
that of past natural history studies.5
Methods
VX-210 is under investigation as a potential therapy for acute
cervical SCI in the phase 2b/3 SPinal Cord Injury Rho INhibition
InvestiGation (SPRING) trial. This article presents the design of
the SPRING trial.
SPRING is a multicenter, phase 2b/3, randomized, double-blind,
placebo-controlled trial of VX-210 (NCT02669849), which is
currently enrolling patients with acute traumatic cervical SCI
(Fig. 3).35 Approximately 100 patients will be enrolled at about 45
sites in the United States and Canada (Table 1). The primary ob-
jective of this trial is to evaluate the efficacy and safety of VX-210
treatment. The primary endpoint, change from baseline in upper
extremity motor score (UEMS) at 6 months, has been selected as a
FIG. 2. Penetration of VX-210 into spinal cord tissue. (A) Ex-
tradural administration and penetration into spinal cord tissue. (B)
VX-210 relative penetration into spinal cord tissue in a post-
mortem pig model after administration of a 1-mg dose. SCI, spinal
cord injury.
FIG. 3. Study design of the phase 2b/3 SPRING trial. AIS, American Spinal Injury Association Impairment Scale; SCI, spinal cord
injury. aApplication of VX-210/placebo occurs during decompression/stabilization surgery. bAll post-treatment follow-up dates occur
within –7 days.
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measure of clinically meaningful neurological improvement. Given
that each of the muscles evaluated in the UEMS assessment is
critical for daily function, small increases in UEMS can correspond
to clinically meaningful improvements in functional recovery.
Total motor score is not appropriate because 1) it assesses con-
traction strength of 10 key muscles in the upper and lower ex-
tremities on each side of the body and does not evaluate muscle
groups by the potential for function or the functional value of an
increase in score, and 2) the mechanism of action and target en-
gagement would dictate a primary assessment focused on regen-
eration and sprouting local to the injury site. Secondary endpoints
include examination of the effects of VX-210 on functional re-
covery by both question- and task-based assessments, change in
AIS grade, and change in motor level.
Inclusion/exclusion criteria
Key inclusion and exclusion criteria for the study are summa-
rized in Table 2. Eligible patients are between 14 and 75 years of
age and have an acute traumatic cervical SCI. Patients must have an
AIS grade of A or B; a motor level of C4, C5, C6, or C7 on each side
as determined by a formal International Standards for Neurological
Classification of Spinal Cord Injury (ISNCSCI) examination; and a
screening UEMS of £16 points on each side (maximum total 32/
50). Patients with AIS grade A and a C4 motor level on both sides
must have ‡1 point of motor activity between C5 and T1 on at least
one side; patients with AIS grade B and a C4 motor level on both
sides must have ‡1 point of motor activity between C5 and C7 on at
least one side. Patients must be scheduled to undergo spinal de-
compression/stabilization surgery commencing within 72 h after
the initial injury, and computed tomography (CT) or magnetic
resonance imaging (MRI) results must be consistent with the pa-
tient’s neurological deficit. The subset of patients with C7 SCI
added by protocol amendment was included to expand the range of
eligible patients for the SPRING trial without compromising the
primary analysis of change in UEMS.
Exclusion criteria include body mass index ‡40 kg/m2; acute SCI
from a penetrating gunshot or stab wound, nontraumatic SCI, bra-
chial plexus injury, complete spinal cord transection, or multifocal
SCI; ‡1 upper extremity muscle group untestable during screening
ISNCSCI examination; unconsciousness or mental impairment that
precludes reliable screening ISNCSCI examination; inability to un-
dergo decompression/stabilization surgery commencing within 72 h
post-injury; known immunodeficiency, including human immuno-
deficiency virus (HIV) or the use of immunosuppressive or cancer
chemotherapeutic drugs; breastfeeding or pregnancy; history of an
adverse reaction to a fibrin sealant or its components; any significant
medical or psychiatric comorbidities (e.g., neurological, cardiac,
respiratory, hepatic, renal, bleeding/coagulation disorder, and active
malignancy) that would significantly increase the risk of trial en-
rollment and/or significantly interfere with trial outcomes or as-
sessments, as judged by the investigator; or participation in any other
clinical study for acute SCI without approval by the study sponsor.
Study design
In this double-blind, placebo-controlled study, each patient re-
ceives either a single 9-mg dose of VX-210 in fibrin sealant or a
placebo (buffer solution) in fibrin sealant. The one-time treatment or
placebo is administered by a surgeon directly onto the dura mater of
the spinal cord at the site of injury during spinal cord decompression
and internal stabilization surgery (Fig. 2). Patients are randomized to
the 9-mg or placebo groups at a 1:1 ratio using an interactive Web
or voice response system, with stratification by age (<30 vs. ‡30
years) and AIS grade (A vs. B with sacral pinprick preservation vs.
B without sacral pinprick preservation). VX-210 and placebo are
supplied in 2.0-mL glass vials, and the blinded study drug labeling
complies with applicable local and national regulations. Each clinical
site is provided with formulation preparation instructions and sur-
gical guidelines to promote standardization of VX-210/placebo
preparation and administration processes. All clinical site personnel
are blinded throughout the study; unblinding of an individual pa-
tient’s treatment by the investigator is limited to medical emergen-
cies or urgent clinical situations in which knowledge of the patient’s
study treatment is necessary for clinical management. Follow-up
assessments of recovery in VX-210-treated versus placebo-treated
patients are conducted at 6 weeks and 3, 6, and 12 months post-
treatment (Table 3). Medical, neurological, and functional chan-
ges are evaluated at pre-defined time points, and serum samples are
collected for pharmacokinetic, biomarker, genetic, and immu-
nological analyses. In the phase 1/2a trial, the 9-mg dose was the
highest concentration tested, had a safe and tolerable safety pro-
file,28 and was chosen to maximize target engagement.
Study endpoints
The primary endpoint of this study is the change from baseline in
UEMS at 6 months post-treatment. UEMS is a portion of the
ISNCSCI neurological assessment that focuses on the hand and arm
strength most relevant to individuals with a cervical SCI.36 Muscle
contraction strength is graded in five key arm and hand muscle
Table 1. Clinical Trial Sites for the SPRING
Trial in the United States and Canada
State City Country
Arizona Tucson USA
California Los Angeles USA
California Orange USA
California Sacramento USA
Connecticut New Haven USA
Florida Jacksonville USA
Florida Tampa USA
Georgia Atlanta USA
Georgia Savannah USA
Illinois Chicago USA
Iowa Iowa City USA
Kansas Kansas City USA
Maryland Baltimore USA
Massachusetts Boston USA
Michigan Ann Arbor USA
Minnesota Minneapolis USA
Mississippi Jackson USA
Missouri St Louis USA
New Jersey Camden USA
Ohio Cleveland USA
Ohio Columbus USA
Ohio Toledo USA
Pennsylvania Hershey USA
Pennsylvania Philadelphia USA
Pennsylvania Pittsburgh USA
Utah Salt Lake City USA
Washington Seattle USA
Alberta Calgary Canada
British Columbia Vancouver Canada
Nova Scotia Halifax Canada
Ontario Ottawa Canada
Ontario Toronto Canada
Que´bec Montreal Canada
Que´bec Que´bec City Canada
Saskatchewan Saskatoon Canada
Site and clinical trial information can be found at: www.vertexscitrial
.com or www.clinicaltrials.gov (NCT02669849).
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groups on each side of the body from 0 (total paralysis) to 5
([normal] active movement, full range of motion against gravity,
and full resistance in a functional muscle position expected from an
otherwise unimpaired person), for a total possible UEMS of 50.
Change from baseline to 6 months in UEMS for the VX-210 9-mg
group will be compared to that of the placebo group for the primary
evaluation of efficacy.
Secondary endpoints evaluating functional recovery include 1)
the Spinal Cord Independence Measure III (SCIM III) self-care
subscore (a question-based evaluation of a patient’s ability to feed,
dress, groom, and bathe independently on a daily basis) at 6 months
post-treatment37–39; 2) the capabilities of upper extremity test
(CUE-T) score (an evaluation of a patient’s ability to perform
specific functional movements or tasks with the arms and hands,
such as grasping a pencil, pushing, or lifting a weight) at 6 months
post-treatment40,41; and 3) the graded redefined assessment of
strength, sensibility, and prehension (GRASSP) quantitative pre-
hension score (an assessment of a patient’s ability to perform
specific functions with the arms, hands, and fingers, such as turning
a key in a lock or pouring water in a cup) at 6 months post-
treatment.42–46 Secondary endpoints evaluating neurological re-
covery include AIS grade conversion and motor level change from
baseline to 6 months post-treatment, which are both derivatives of
the ISNCSCI neurological assessment. Pharmacokinetic parame-
ters of VX-210 will also be evaluated. The ISNCSCI, SCIM III,
CUE-T, and GRASSP assessments are conducted by independent
trained assessors. All efforts are made to use the same assessor for a
given efficacy assessment for a given patient.
Safety evaluations include AEs, vital signs, electrocardiograms,
clinical laboratory tests (i.e., serum chemistry, hematology, coag-
ulation, and urinalysis), physical examinations, surgical site ex-
aminations, and immunogenicity measures. Safety and tolerability
data will be reviewed by an independent data monitoring com-
mittee to ensure the safety of patients in the study.
Interim analysis
An interim analysis will be conducted when 33% of enrolled
patients have completed the 6-month follow-up visit, and the study
may be stopped for futility depending on the results of this interim
analysis. An independent data monitoring committee will conduct
the review and make a recommendation to the study sponsor on the
topic of futility.
Statistical analysis
The null hypothesis to be tested is that the mean change from
baseline in UEMS at 6 months post-treatment is the same for the 9-
mg dose of VX-210 and placebo. This null hypothesis will be tested
at a two-sided significance level (a = 0.05). Using a standard de-
viation of 6.0, if the 9-mg VX-210 group improves in UEMS by 4
points more than the placebo group (a clinically meaningful dif-
ference), the approximately 100 study patients (*50 patients/
group) will provide ‡80% power to detect a statistically significant
treatment effect for the 9-mg VX-210 group compared to placebo.
The primary analysis will include those who prematurely terminate
before the 6-month follow-up.
To control the type I error rate, a hierarchical testing procedure
will be used for the important efficacy endpoints. The first endpoint
in the testing hierarchy will be the primary endpoint (change from
Table 2. Eligibility Criteria: Phase 2b/3 SPRING Trial
Key inclusion criteria Key exclusion criteria
Patient
characteristics
 14–75 years, inclusive  Body mass index ‡40 kg/m2
 Breastfeeding or pregnancy
Injury  Acute traumatic cervical SCI  Acute SCI from gunshot or penetrating/stab wound;
nontraumatic SCI; brachial plexus injury; complete
spinal cord transection; or multi-focal SCI
Neurological
impairment
 Motor level of C4, C5, C6, or C7 on each side
– Screening UEMS score must be £16 points on
each side.
– Patients with AIS grade A and a C4 motor level
on both sides must have at least 1 point of motor
activity between C5 and T1 on at least 1 side.
– Patients with AIS grade B and a C4 motor level
on both sides must have at least 1 point of motor
activity between C5 and C7 on at least 1 side.
 AIS grade A or B
 ‡1 upper extremity muscle group untestable during
screening ISNCSCI examination
 Unconsciousness or other mental impairment that
precludes reliable ISNCSCI examination
Decompression/
stabilization
 Scheduled and planned to undergo spinal cord
decompression/stabilization surgery commencing
within 72 h post-injury
 Inability to undergo decompression/stabilization
surgery commencing within 72 h post-injury
Other  CT or MRI consistent with neurological deficit  Participation in any other clinical study for acute SCI
without approval by the sponsor
 Known immunodeficiency, including HIV or use of
immunosuppressive or cancer chemotherapeutic
drugs
 History of an adverse reaction to a fibrin sealant or its
components
 Any significant medical or psychiatric comorbidities
that would significantly increase the risk of study
enrollment or significantly interfere with study out-
comes or assessments, as judged by the investigator
AIS, American Spinal Injury Association Impairment Scale; CT, computed tomography; HIV, human immunodeficiency virus; ISNCSCI, International
Standards for Neurological Classification of Spinal Cord Injury; MRI, magnetic resonance imaging; SCI, spinal cord injury; UEMS, upper extremity
motor score.
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baseline in UEMS at 6 months post-treatment). The second end-
point in the testing hierarchy will be the SCIM III self-care subscore
at 6 months post-treatment. Treatment effects will be analyzed for
each time point.
Ethics and informed consent
The study is being conducted in accord with the current Inter-
national Conference on Harmonisation Guideline for Good Clinical
Practice (ICH GCP), which is consistent with the ethical principles
founded in the Declaration of Helsinki, and in accord with local
applicable laws and regulations. An institutional review board
(IRB) or independent ethics committee (IEC) reviews all appro-
priate study documentation to safeguard the rights, safety, and well-
being of the patients. The study is only conducted at sites where
IRB/IEC approval has been obtained.
After the study has been fully explained, the patient (or a witness
or legally appointed and authorized representative) signs and dates
an informed consent form before study participation. The method
of obtaining and documenting the informed consent and assent (if
applicable) and the contents of the consent comply with the ICH
GCP and all applicable laws and regulations.
Conclusions
Substantial preclinical data support Rho overactivation as a key
step in the inhibition of motor neurite outgrowth and promotion of
neuronal apoptosis post-SCI. Inhibition of Rho thus represents a
potential treatment for SCI. VX-210 is an investigational inhibitor
of Rho. The phase 2b/3 SPRING trial (ClinicalTrials.gov identifier:
NCT02669849) tests the hypothesis that VX-210 applied to the
(extradural) dura mater diffuses into the spinal cord and augments
motor recovery after acute cervical SCI. The SPRING trial is
currently enrolling patients with acute cervical SCI throughout the
United States and Canada.
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